/ENTX
ENTX Stock - Entera Bio Ltd.
Healthcare|BiotechnologyNASDAQ
$1.77-8.76%
$0.17 (-8.76%) • Dec 19
51
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.23
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.51
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.95
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ENTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.75 – $1.79
TARGET (TP)$2.04
STOP LOSS$1.63
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.71
52W High$3.22
52W Low$1.50
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $181,000 | N/A | $134,000 | $571,000 | $365,000 |
| Gross Profit | $9,000 | $-56,000 | $-31,000 | $198,000 | $65,000 |
| Gross Margin | 5.0% | N/A | -23.1% | 34.7% | 17.8% |
| Operating Income | $-9,585,000 | $-8,940,000 | $-13,068,000 | $-12,217,000 | $-11,168,000 |
| Net Income | $-9,541,000 | $-8,889,000 | $-13,071,000 | $-12,187,000 | $-11,216,000 |
| Net Margin | -5271.3% | N/A | -9754.5% | -2134.3% | -3072.9% |
| EPS | $-0.25 | $-0.31 | $-0.45 | $-0.47 | $-0.54 |
Company Overview
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ENTXBeat Rate
68%
Last 19 quarters
Avg Surprise
+8.6%
EPS vs Estimate
Beats / Misses
13/5
1 met exactly
Latest EPS
$-0.07
Q4 2025
EPS Surprise History
Q1 24
+12.5%
$-0.07vs$-0.08
Q2 24
+16.7%
$-0.05vs$-0.06
Q3 24
0.0%
$-0.06vs$-0.06
Q4 24
-60.0%
$-0.08vs$-0.05
Q1 25
+25.0%
$-0.06vs$-0.08
Q2 25
+14.3%
$-0.06vs$-0.07
Q3 25
+45.5%
$-0.06vs$-0.11
Q4 25
+22.2%
$-0.07vs$-0.09
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 27, 2026 | $-0.11 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.09 | $-0.07 | +22.2% | ✓ BEAT |
Q3 2025 | Aug 8, 2025 | $-0.11 | $-0.06 | +45.5% | ✓ BEAT |
Q2 2025 | May 9, 2025 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q1 2025 | Mar 28, 2025 | $-0.08 | $-0.06 | +25.0% | ✓ BEAT |
Q4 2024 | Nov 8, 2024 | $-0.05 | $-0.08 | -60.0% | ✗ MISS |
Q3 2024 | Aug 9, 2024 | $-0.06 | $-0.06 | 0.0% | = MET |
Q2 2024 | May 10, 2024 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q1 2024 | Mar 8, 2024 | $-0.08 | $-0.07 | +12.5% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q3 2023 | Aug 11, 2023 | $-0.07 | $-0.08 | -14.3% | ✗ MISS |
Q2 2023 | May 5, 2023 | $-0.12 | $-0.08 | +33.3% | ✓ BEAT |
Q1 2023 | Mar 27, 2023 | $-0.11 | $-0.11 | -1.3% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.16 | $-0.11 | +31.3% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.13 | $-0.11 | +15.4% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.16 | $-0.13 | +18.8% | ✓ BEAT |
Q1 2022 | Mar 8, 2022 | $-0.11 | $0.21 | +290.9% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.10 | $-0.05 | +50.0% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | $-0.10 | $-0.19 | -90.0% | ✗ MISS |
Q2 2021 | May 20, 2021 | $-0.12 | $-0.43 | -258.3% | ✗ MISS |
Latest News
Entera Bio Q3 EPS $(0.07) Beats $(0.09) Estimate
📈 PositiveBenzinga•Nov 14, 2025, 09:14 PM
Entera Bio Presents New Clinical Data From Phase 2 Study Of EB613 At 2025 North American Menopause Society Annual Meeting; Intends To Initiate Global Registrational Phase 3 Trial After July 2025 FDA Concurrence
📈 PositiveBenzinga•Oct 23, 2025, 01:05 PM
Entera Bio Releases New Phase 2 Data At NAMS 2025 Showing That EB613, An Oral PTH[1-34] Therapy, Consistently Increased Bone Mineral Density In Both Early Postmenopausal Women And Those 10 Years Post-Menopause
📈 PositiveBenzinga•Oct 23, 2025, 12:58 PM
Entera Bio Announces It Will Present New Phase 2 Clinical Data For EB613 At The North American Menopause Society 2025 Annual Meeting, October 21–25, 2025, In Orlando, Florida.
📈 PositiveBenzinga•Oct 16, 2025, 12:47 PM
Entera Bio Presents Preclinical Data For OPK-8801003, Oral GLP-2 Tablet With Longer Half-Life Aiming To Replace Daily Injections For Short Bowel Syndrome Patients
📈 PositiveBenzinga•Sep 15, 2025, 01:05 PM
Entera Bio To Present EB613 Phase 2 Data At ASBMR 2025; Oral Anabolic Tablet Advances Toward Phase 3
📈 PositiveBenzinga•Sep 8, 2025, 12:33 PM
Frequently Asked Questions about ENTX
What is ENTX's current stock price?
Entera Bio Ltd. (ENTX) is currently trading at $1.77 per share. The stock has moved -8.76% today.
What is the analyst price target for ENTX?
No analyst price targets are currently available for this stock.
What sector is Entera Bio Ltd. in?
Entera Bio Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ENTX's market cap?
Entera Bio Ltd. has a market capitalization of $0.08 billion, making it a small-cap company.
Does ENTX pay dividends?
No, Entera Bio Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABOS
Acumen Pharmaceuticals, Inc.
$2.15
Mkt Cap: $0.1B
AGEN
Agenus Inc.
$3.44
Mkt Cap: $0.1B
ANIX
Anixa Biosciences, Inc.
$3.30
Mkt Cap: $0.1B
HURA
TuHURA Biosciences, Inc.
$0.82
Mkt Cap: $0.0B
INO
Inovio Pharmaceuticals, Inc.
$2.28
Mkt Cap: $0.1B
IRD
Opus Genetics, Inc.
$2.00
Mkt Cap: $0.1B
MCRB
Seres Therapeutics, Inc.
$14.98
Mkt Cap: $0.1B
SEER
Seer, Inc.
$1.79
Mkt Cap: $0.1B
SPRO
Spero Therapeutics, Inc.
$2.32
Mkt Cap: $0.1B
VTGN
VistaGen Therapeutics, Inc.
$0.78
Mkt Cap: $0.0B
Explore stocks similar to ENTX for comparison